Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Angiostatin activating agent polypeptide and application thereof

An angiostatin and activator technology, applied in the field of angiostatin activator polypeptides, to achieve the effect of improving survival rate and inhibiting proliferation activity

Inactive Publication Date: 2015-06-10
SUZHOU PULUODA BIOLOGICAL SCI & TECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no well-developed angiostatin activator polypeptide available for the treatment of malignant tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Activity of angiostatin activator polypeptides on the hydrolysis of plasminogen in vitro.

[0016] Angiostatin, the hydrolyzate of plasminogen, was detected by ELISA. Using 1ml of 1mg / ml plasmin as the substrate, add 5, 10, and 20ng of angiostatin activator polypeptide (synthesized by Shanghai Sangong) and 60ng of positive control drug metalloprotease to the substrate solution respectively. ℃, after reacting for 5 minutes, centrifuge, take the supernatant, and use the ELISA method to react the content of angiostatin in the solution. The results show that the angiostatin produced by 5, 10, and 20ng of angiostatin activator polypeptide and metalloprotease are respectively 105.69, 489.47, 1547.12 μM.

Embodiment 2

[0018] IC50 of angiostatin activator polypeptide on the growth and survival of human vascular endothelial cells cultured in vitro.

[0019] Using the MTT colorimetric method. The logarithmic growth of human vascular endothelial cells HUVEC was added to a 96-well culture plate at 1.0×105, and cultured for 24 hours. Different concentrations of the experimental drug angiostatin activator polypeptide (Shanghai Sangong Synthetic Co., Ltd.) were added to the experimental wells and positive drug control wells respectively. ) and the positive control drug paclitaxel; the same volume of solvent was added to the blank group. Set up five duplicate wells per well, culture for 48h, add MTT to each well at 0h, 2h, 8h, 14h, 20h, 24h, 36h, and 48h respectively, add DMSO after 4h, incubate for 30min, and incubate at 620nm in a microplate reader. Measure the absorbance A value, according to the formula HUVEC growth inhibition rate=(1-absorbance value of the experimental group / absorbance value ...

Embodiment 3

[0021] The in vivo activity of angiostatin activator polypeptide was detected by tumor model.

[0022] The prostate cancer tumor model was established, and the positive control drug paclitaxel was added; the same volume of solvent was added to the blank group, and three doses of polypeptide (Shanghai Sangong Synthetic) were set in the experimental group: 0.75, 1.5, and 3 mg / Kg. After 21 days, the number of surviving mice was observed, and the survival rate was calculated. The results showed that the angiostatin activator polypeptide can effectively protect mice and improve the survival rate of tumor-bearing mice, with the survival rate reaching 76.3%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of drugs, in particular to a polypeptide having functions of activating angiostatin and treating malignant tumor. The sequence of the polypeptide is a novel sequence of DEQWLMYPLFHSGLF, and the polypeptide can activate angiostatin in vitro, restrain vascular endothelial cells from proliferating, and improve the survival rate of tumor-bearing mice in vivo tests, thereby having potential development values of new drugs.

Description

technical field [0001] The invention relates to angiostatin activator polypeptide and application thereof, in particular to a polypeptide capable of activating angiostatin and treating malignant tumors. Background technique [0002] In 1971, Folkman proposed that tumor growth and metastasis depend on angiogenesis. It is also believed that after the formation of a solid tumor, its development can be divided into two stages: the avascular phase and the vascular phase. In the avascular stage, the existence of tiny tumors depends on the diffuse blood supply of the surrounding interstitium, the growth rate is linear, the tumor is limited within 1mm to 2mm, and the number of tumor cells is less than 10 5 ~10 6 One, forcing the tumor to be in a "dormant state"; after entering the vascular phase, the tumor tissue is perfused with blood supply, and the tumor grows exponentially, and can increase by 16,000 times after 2 weeks. New blood vessels not only provide the nutrients and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08A61K38/10A61P35/00
Inventor 罗瑞雪
Owner SUZHOU PULUODA BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com